Published in BJU Int on November 11, 2010
CUA guideline on adult overactive bladder. Can Urol Assoc J (2017) 1.08
Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. Int J Clin Pract (2013) 1.03
A phase II dose-ranging study of mirabegron in patients with overactive bladder. Int Urogynecol J (2013) 0.98
Does the Urinary Microbiome Play a Role in Urgency Urinary Incontinence and Its Severity? Front Cell Infect Microbiol (2016) 0.89
Changes in nerve growth factor level and symptom severity following antibiotic treatment for refractory overactive bladder. Int Urogynecol J (2013) 0.85
Content validity and test-retest reliability of Patient Perception of Intensity of Urgency Scale (PPIUS) for overactive bladder. BMC Urol (2012) 0.80
Overactive bladder. F1000Res (2015) 0.79
Efficacy and safety of intravesical onabotulinumtoxinA injection on elderly patients with chronic central nervous system lesions and overactive bladder. PLoS One (2014) 0.79
Association of urinary urgency and delay time of micturition in women with overactive bladder. Int Neurourol J (2014) 0.77
Neurogenic mechanisms in bladder and bowel ageing. Biogerontology (2015) 0.75
Prospective randomized comparison of the transobturator mid-urethral sling with the single-incision sling among women with stress urinary incontinence: 1-year follow-up study. Int Urogynecol J (2015) 0.75
The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn (2002) 22.80
The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology (2003) 9.92
The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Am J Obstet Gynecol (2002) 4.31
Is there a synergistic effect of topical oestrogens when administered with antimuscarinics in the treatment of symptomatic detrusor overactivity? Eur Urol (2008) 2.12
Urinary incontinence at orgasm: relation to detrusor overactivity and treatment efficacy. Eur Urol (2007) 2.11
Overactive bladder symptoms: do we need urodynamics? Neurourol Urodyn (2003) 2.07
FOR: women should be free to opt for cosmetic genital surgery. BJOG (2014) 1.94
Can ultrasound replace ambulatory urodynamics when investigating women with irritative urinary symptoms? BJOG (2002) 1.74
Defining cure. Neurourol Urodyn (2011) 1.72
P-QOL: a validated questionnaire to assess the symptoms and quality of life of women with urogenital prolapse. Int Urogynecol J Pelvic Floor Dysfunct (2004) 1.61
Pregnancy and delivery following tension-free vaginal tape. Int Urogynecol J Pelvic Floor Dysfunct (2006) 1.60
Validation of the Patient Global Impression of Improvement (PGI-I) for urogenital prolapse. Int Urogynecol J (2009) 1.60
Nocturia Think Tank: focus on nocturnal polyuria: ICI-RS 2011. Neurourol Urodyn (2012) 1.56
Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int (2006) 1.50
Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome. Int J Urol (2006) 1.50
Urethral diverticula: a diagnostic dilemma. BJU Int (2004) 1.49
The effect of mode of delivery on pelvic floor functional anatomy. Int Urogynecol J Pelvic Floor Dysfunct (2007) 1.48
Antimuscarinic drugs to treat overactive bladder. BMJ (2012) 1.44
Constructing trials to show whether urodynamic studies are necessary in lower urinary tract dysfunction. Neurourol Urodyn (2011) 1.43
Design and validation of a new screening instrument for lower urinary tract dysfunction: the bladder control self-assessment questionnaire (B-SAQ). Eur Urol (2006) 1.43
Is there a difference between women with or without detrusor overactivity complaining of symptoms of overactive bladder? BJU Int (2013) 1.41
Quality control in urodynamics: Analysis of an international multi-center study. Neurourol Urodyn (2009) 1.40
Transdermal oxybutynin: sticking to the facts. Eur Urol (2006) 1.39
Role of urodynamics before prolapse surgery. Int Urogynecol J (2014) 1.39
The efficacy and safety of PSD503 (phenylephrine 20%, w/w) for topical application in women with stress urinary incontinence. A phase II, multicentre, double-blind, placebo controlled, 2-way cross over study. Eur J Obstet Gynecol Reprod Biol (2011) 1.39
Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol Urodyn (2009) 1.37
Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. Curr Opin Urol (2009) 1.19
Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Neurourol Urodyn (2013) 1.17
A double-blind placebo-controlled trial on the effects of 25 mg estradiol implants on the urge syndrome in postmenopausal women. Int Urogynecol J Pelvic Floor Dysfunct (2003) 1.16
Publish or be damned? The fate of abstracts presented at the International Continence Society Meeting 2003. Neurourol Urodyn (2007) 1.11
Interstitial cystitis: diagnosis and management. Eur J Obstet Gynecol Reprod Biol (2012) 1.08
A review of adherence to drug therapy in patients with overactive bladder. BJU Int (2008) 1.06
The effect of hormones on the lower urinary tract. Menopause Int (2013) 1.06
Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU Int (2005) 1.06
A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome. BJU Int (2007) 1.03
Selection of patients in whom vaginal graft use may be appropriate. Consensus of the 2nd IUGA Grafts Roundtable: optimizing safety and appropriateness of graft use in transvaginal pelvic reconstructive surgery. Int Urogynecol J (2012) 1.03
Surgical treatment for female stress urinary incontinence: what is the gold-standard procedure? Int Urogynecol J Pelvic Floor Dysfunct (2009) 1.02
Technique of urethral retro-resistance pressure measurement. Neurourol Urodyn (2004) 1.00
Overactive bladder syndrome in older people. BJU Int (2007) 0.99
Overactive bladder: Is there a link to the metabolic syndrome in men? Neurourol Urodyn (2010) 0.98
Is there a discrepancy between patient and physician quality of life assessment? Neurourol Urodyn (2009) 0.96
Normative bladder diary measurements: night versus day. Neurourol Urodyn (2007) 0.96
What are the causes and consequences of bladder overdistension? ICI-RS 2011. Neurourol Urodyn (2012) 0.95
Oestrogens and overactive bladder. Neurourol Urodyn (2013) 0.94
Bladder diary volume per void measurements in detrusor overactivity. J Urol (2006) 0.94
Psychological morbidity and female urinary incontinence. Best Pract Res Clin Obstet Gynaecol (2007) 0.92
Can we prevent incontinence? ICI-RS 2011. Neurourol Urodyn (2012) 0.91
A prospective observational trial of pelvic floor muscle training for female stress urinary incontinence. BJU Int (2006) 0.90
Sonographic transvaginal bladder wall thickness: does the measurement discriminate between urodynamic diagnoses? Neurourol Urodyn (2010) 0.90
Oxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladder. Expert Opin Pharmacother (2009) 0.90
How should bladder wall thickness be measured? A comparison of vaginal, perineal and abdominal ultrasound. Neurourol Urodyn (2010) 0.89
Bladder diary patterns in detrusor overactivity and urodynamic stress incontinence. Neurourol Urodyn (2007) 0.89
Bladder diary measurements in asymptomatic females: functional bladder capacity, frequency, and 24-hr volume. Neurourol Urodyn (2007) 0.88
Antidiuresis therapy: mechanism of action and clinical implications. Neurourol Urodyn (2007) 0.88
Overactive bladder: diagnosis and management. Maturitas (2011) 0.88
Three-dimensional ultrasound of the urethral sphincter predicts continence surgery outcome. Neurourol Urodyn (2009) 0.87
Estrogens and the lower urinary tract. Neurourol Urodyn (2011) 0.86
Preoperative pressure-flow studies: useful variables to predict the outcome of continence surgery. BJU Int (2004) 0.86
A longitudinal investigation of the impact of typology of urinary incontinence on quality of life during midlife: results from a British prospective study. Maturitas (2009) 0.86
Solifenacin: as effective in mixed urinary incontinence as in urge urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct (2005) 0.85
Inter-observer reliability of digital vaginal examination using a four-grade scale in different patient positions. Int Urogynecol J Pelvic Floor Dysfunct (2008) 0.85
Nocturia research: current status and future perspectives. Neurourol Urodyn (2010) 0.85
Reliability and normal ranges for the Patient's Perception of Intensity of Urgency Scale in asymptomatic women. BJU Int (2009) 0.84
Inter-observer reliability of three different methods of measuring urethrovesical mobility. Int Urogynecol J Pelvic Floor Dysfunct (2008) 0.84
Preventing urinary incontinence in women. Curr Opin Obstet Gynecol (2013) 0.84
Patient-selected goals in overactive bladder: a placebo controlled randomized double-blind trial of transdermal oxybutynin for the treatment of urgency and urge incontinence. BJU Int (2011) 0.84
Successful use of the B-Lynch brace suture in early pregnancy. J Obstet Gynaecol (2004) 0.84
Fourth international consultation on incontinence-research society 2013. Neurourol Urodyn (2014) 0.84
Is there a difference in patient and physician quality of life evaluation in pelvic organ prolapse? Int Urogynecol J Pelvic Floor Dysfunct (2007) 0.84
Validation of the pelvic organ prolapse quantification (POP-Q) system in left lateral position. Int Urogynecol J Pelvic Floor Dysfunct (2009) 0.83
Long-term prospective randomized study comparing two different regimens of oxybutynin as a treatment for detrusor overactivity. Eur J Obstet Gynecol Reprod Biol (2005) 0.83
Total urgency and frequency score as a measure of urgency and frequency in overactive bladder and storage lower urinary tract symptoms. BJU Int (2014) 0.82
Management of overactive bladder syndrome. Postgrad Med J (2007) 0.82
Special considerations in premenopausal and postmenopausal women with symptoms of overactive bladder. Urology (2002) 0.82
New drug treatments for urinary incontinence. Maturitas (2010) 0.82
Does our limited knowledge of the mechanisms of neural stimulation limit its benefits for patients with overactive bladder? ICI-RS 2013. Neurourol Urodyn (2014) 0.82
Menopausal transition and the risk of urinary incontinence: results from a British prospective cohort. BJU Int (2010) 0.82
Phase II drugs that target cholinergic receptors for the treatment of overactive bladder. Expert Opin Investig Drugs (2014) 0.81
Mixed incontinence: current evidence and future perspectives. Neurourol Urodyn (2010) 0.81
Usage of International Continence Society standardized terminology: A bibliometric and questionnaire study. Neurourol Urodyn (2010) 0.81